Abstract
Background High-flow nasal cannula (HFNC) is an alternative for delivering respiratory support to adults with acute exacerbations of chronic obstructive pulmonary disease. Despite increased popularity for respiratory support, there is still uncertainty about if their l costs of justify the clinical benefits provided. This study aims to evaluate the cost-utility of HFNC in acute exacerbations of chronic obstructive pulmonary disease in Colombia
Methods Using a decision tree model, we estimated the cost and quality-adjusted life-years (QALYs) associated with HFNC and conventional oxygen therapy (COT) in adults who presented to the emergency department with acute exacerbations of chronic obstructive pulmonary disease. All parameters for the model were derived from published research with local data. All analyses were done from a societal perspective.
Results We estimate a gain of 0,49 and 0,48 QALYs per patient-year on HFNC and COT respectively, and a difference of US$314 in total discounted cost per person-year on HFNC respecting COT. Because HFNC was associated with lower costs compared to conventional therapy, the incremental cost effectiveness ratio was not calculated.
Conclusions HFNC achieving better outcomes at a lower cost in patients with acute exacerbations of chronic obstructive pulmonary disease in Colombia. Evidence should continue to be generated with real-life effectiveness data and economic evaluations in other countries to confirm our findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial disclosures: This study was supported by own funding of authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors